Cargando…
Who, what, and when—effective therapy for severe COVID-19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598210/ https://www.ncbi.nlm.nih.gov/pubmed/34812425 http://dx.doi.org/10.1016/S2665-9913(21)00353-2 |
| _version_ | 1784600767913525248 |
|---|---|
| author | Kelmenson, Daniel A Cron, Randy Q |
| author_facet | Kelmenson, Daniel A Cron, Randy Q |
| author_sort | Kelmenson, Daniel A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8598210 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85982102021-11-18 Who, what, and when—effective therapy for severe COVID-19 Kelmenson, Daniel A Cron, Randy Q Lancet Rheumatol Comment Elsevier Ltd. 2022-01 2021-11-17 /pmc/articles/PMC8598210/ /pubmed/34812425 http://dx.doi.org/10.1016/S2665-9913(21)00353-2 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Kelmenson, Daniel A Cron, Randy Q Who, what, and when—effective therapy for severe COVID-19 |
| title | Who, what, and when—effective therapy for severe COVID-19 |
| title_full | Who, what, and when—effective therapy for severe COVID-19 |
| title_fullStr | Who, what, and when—effective therapy for severe COVID-19 |
| title_full_unstemmed | Who, what, and when—effective therapy for severe COVID-19 |
| title_short | Who, what, and when—effective therapy for severe COVID-19 |
| title_sort | who, what, and when—effective therapy for severe covid-19 |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598210/ https://www.ncbi.nlm.nih.gov/pubmed/34812425 http://dx.doi.org/10.1016/S2665-9913(21)00353-2 |
| work_keys_str_mv | AT kelmensondaniela whowhatandwheneffectivetherapyforseverecovid19 AT cronrandyq whowhatandwheneffectivetherapyforseverecovid19 |